MCID: FML037
MIFTS: 50

Female Breast Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Female Breast Cancer

Aliases & Descriptions for Female Breast Cancer:

Name: Female Breast Cancer 12 14
Female Breast Carcinoma 12 14 69
Malignant Neoplasm of Female Breast 69
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 47 C2918
UMLS 69 C0007104

Summaries for Female Breast Cancer

Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to breast cancer and aortitis. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Pathways in cancer and Chks in Checkpoint Regulation. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, prostate and whole blood, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
id Related Disease Score Top Affiliating Genes
1 breast cancer 10.5
2 aortitis 10.3 PGR TP53
3 mouth disease 10.3 ERBB2 PGR
4 pericardium leiomyoma 10.3 PGR TP53
5 autoimmune disease of cardiovascular system 10.3 BRCA2 PGR
6 heart malignant hemangiopericytoma 10.3 BRCA2 PGR
7 bartholin's gland benign neoplasm 10.3 ESR1 PGR
8 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
9 appendix leiomyoma 10.3 ESR1 PGR
10 bronchus adenoma 10.3 ESR1 PGR
11 kunjin encephalitis 10.3 BRCA2 ERBB2
12 ovarian benign neoplasm 10.3 ESR1 PGR
13 plexiform neurofibroma 10.3 ESR1 PGR
14 malt worker's lung 10.3 KLK3 TP53
15 bladder clear cell adenocarcinoma 10.3 ESR1 TP53
16 paranasal sinus disease 10.3 ESR1 PGR
17 casp10-related autoimmune lymphoproliferative syndrome 10.3 BRCA2 PHB
18 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
19 triple-receptor negative breast cancer 10.3 ERBB2 PGR
20 breast pericanalicular fibroadenoma 10.3 BRCA2 PGR TP53
21 breast ductal carcinoma 10.2 PGR TP53
22 deafness, autosomal recessive 21 10.2 ESR1 PGR
23 reticulosarcoma 10.2 AR TP53
24 skin sarcoma 10.2 ERBB2 PGR
25 cystinosis, nephropathic 10.2 ERBB2 TP53
26 atypical lipomatous tumor 10.2 ESR1 PGR
27 lung clear cell-sugar-tumor 10.2 BRCA2 ERBB2 TP53
28 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
29 reactive arthritis 10.2 ERBB2 PGR TP53
30 bladder colloid adenocarcinoma 10.2 BRCA2 ERBB2 TP53
31 mycobacterium kansasii 10.2 BRCA2 TP53 XRCC1
32 vaginal adenosarcoma 10.2 ESR1 PGR TP53
33 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
34 adult central nervous system mature teratoma 10.2 ERBB2 TP53 XRCC1
35 acinar cell carcinoma 10.2 PGR TP53
36 glioma 10.2 ERBB2 ESR1 PGR
37 hereditary breast ovarian cancer 10.2 ERBB2 ESR1
38 oro-mandibular-limb hypogenesis syndrome 10.2 ERBB2 TP53 XRCC1
39 biliary tract neoplasm 10.2 ESR1 KLK3 PGR
40 cervical lymphoepithelioma-like carcinoma 10.2 ERBB2 ESR1 PGR
41 histiocytic and dendritic cell cancer 10.2 ERBB2 ESR1 PGR
42 her2-receptor negative breast cancer 10.2 ERBB2 ESR1 PGR
43 intestinal perforation 10.2 ESR1 PGR
44 tamoxifen-related endometrial lesion 10.2 ERBB2 TP53 XRCC1
45 rectal neoplasm 10.2 ERBB2 ESR1 PGR
46 combined t cell and b cell immunodeficiency 10.2 ERBB2 ESR1 PGR
47 anomalous left coronary artery from the pulmonary artery 10.2 ERBB2 ESR1 PGR
48 anus adenocarcinoma 10.2 ERBB2 ESR1 PGR
49 sclerosing hemangioma 10.2 ERBB2 ESR1 PGR
50 rhinitis 10.2 ESR1 KLK3 TP53

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.1 ATM BRCA2 CDKN1B PALB2 TP53 XRCC1

MGI Mouse Phenotypes related to Female Breast Cancer:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ERBB2 ESR1 PALB2 PGR TP53 XRCC1
2 behavior/neurological MP:0005386 10.2 PGR TP53 XRCC1 AR ATM BRCA2
3 growth/size/body region MP:0005378 10.2 AR ATM BRCA2 CDKN1B CYP1A1 ERBB2
4 cardiovascular system MP:0005385 10.19 AR ATM CDKN1B CYP1A1 ERBB2 ESR1
5 endocrine/exocrine gland MP:0005379 10.18 AR ATM BRCA2 CDKN1B CYP1A1 ERBB2
6 homeostasis/metabolism MP:0005376 10.17 AR ATM BRCA2 CDKN1B CYP1A1 ERBB2
7 embryo MP:0005380 10.15 PALB2 PGR TP53 XRCC1 AR ATM
8 integument MP:0010771 10.1 AR ATM BRCA2 CDKN1B ERBB2 ESR1
9 mortality/aging MP:0010768 10.1 AR ATM BRCA2 CDKN1B CYP1A1 ERBB2
10 digestive/alimentary MP:0005381 9.99 AR BRCA2 CDKN1B ERBB2 ESR1 TP53
11 neoplasm MP:0002006 9.96 PALB2 PGR TP53 XRCC1 AR ATM
12 limbs/digits/tail MP:0005371 9.91 ESR1 PALB2 PGR TP53 AR BRCA2
13 nervous system MP:0003631 9.81 AR ATM BRCA2 CDKN1B ERBB2 ESR1
14 normal MP:0002873 9.56 AR BRCA2 CYP1A1 ERBB2 ESR1 PGR
15 reproductive system MP:0005389 9.28 AR ATM BRCA2 CDKN1B ERBB2 ESR1

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 868)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
6
Lenograstim Approved Phase 4,Phase 3,Phase 1,Phase 2 135968-09-1
7
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
8
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120511-73-1 2187
9
Diazepam Approved, Illicit, Vet_approved Phase 4 439-14-5 3016
10
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
11
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10540-29-1 2733526
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
14
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-28-2 5757 53477783
15
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2 71-58-9
16
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
20
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
21
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
22
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
23
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
24
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
25
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Palbociclib Approved Phase 4,Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
27
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 104741 17756771
28
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 180288-69-1 9903
29
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
30
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
31
Megestrol acetate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 595-33-5 11683
32
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
33
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
34
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
35
Lactulose Approved Phase 4 4618-18-2 11333
36
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
37
Ropivacaine Approved Phase 4,Phase 2,Phase 3 84057-95-4 71273 175805
38
Bazedoxifene Approved, Investigational Phase 4,Phase 3,Phase 2 198481-32-2
39
Aprepitant Approved, Investigational Phase 4,Phase 3,Phase 2 170729-80-3 151165 6918365
40
Fosaprepitant Approved Phase 4,Phase 3,Phase 2 172673-20-0 219090
41
Granisetron Approved, Investigational Phase 4,Phase 3 109889-09-0 3510
42
Ondansetron Approved Phase 4,Phase 3,Phase 2 99614-02-5 4595
43
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 5595
44
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
45
Sulbactam Approved Phase 4 68373-14-8
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
47
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
48
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
49
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 2180-92-9, 38396-39-3 2474
50
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 3521)
id Name Status NCT ID Phase
1 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4
2 Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women Unknown status NCT01069211 Phase 4
3 Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer Unknown status NCT00352872 Phase 4
4 National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations Unknown status NCT00413491 Phase 4
5 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
6 Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene Unknown status NCT01072318 Phase 4
7 Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors Unknown status NCT00111241 Phase 4
8 The MONET - Study: MR Mammography of Nonpalpable Breast Tumors Unknown status NCT00302120 Phase 4
9 Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer Unknown status NCT00484614 Phase 4
10 Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer Unknown status NCT01612871 Phase 4
11 WHAT (Women, Hot-flashes, Activity, Trial) - Physical Activity for Treatment of Hot Flushes Among Postmenopausal Women Unknown status NCT01282320 Phase 4
12 Aromatase Inhibitor Clinical Trial Unknown status NCT00228956 Phase 4
13 Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer Unknown status NCT02158299 Phase 4
14 Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma Unknown status NCT00307606 Phase 4
15 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
16 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4
17 Promoting Breast Cancer Screening in Non-adherent Women Completed NCT01332032 Phase 4
18 Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment Completed NCT01859936 Phase 4
19 A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer Completed NCT00544986 Phase 4
20 Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer Completed NCT00014638 Phase 4
21 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4
22 Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women Completed NCT00237133 Phase 4
23 Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole Completed NCT00237224 Phase 4
24 A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Completed NCT00121836 Phase 4
25 Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer Completed NCT00493350 Phase 4
26 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed NCT00485953 Phase 4
27 Wellbutrin XL, Major Depressive Disorder and Breast Cancer Completed NCT00234195 Phase 4
28 Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00022386 Phase 4
29 A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer Completed NCT00649090 Phase 4
30 Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast Cancer Completed NCT00688909 Phase 4
31 Accelerated Radiotherapy Outcomes in Women Completed NCT00156130 Phase 4
32 Pregabalin for Postoperative Pain in Women Undergoing Breast Cancer Surgery Completed NCT00785382 Phase 4
33 Arthralgia During Anastrozole Therapy for Breast Cancer Completed NCT00323479 Phase 4
34 Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Rlisk Completed NCT00839696 Phase 4
35 Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer Completed NCT00160901 Phase 4
36 Chlorhydrate of Ropivacaine and Breast Cancer Surgery Completed NCT00370240 Phase 4
37 Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer Completed NCT00375752 Phase 4
38 Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density Completed NCT00418236 Phase 4
39 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4
40 Post Market Study Using the Xoft Axxent System Completed NCT01017549 Phase 4
41 A Study of Avastin With Taxane Therapy in Patients With Triple Negative Breast Cancer Completed NCT01094184 Phase 4
42 Randomized Trial of Follow-up Strategies in Breast Cancer Completed NCT00156039 Phase 4
43 Life Quality and Mental State in Patients With Breast Cancer Completed NCT01458457 Phase 4
44 Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients Completed NCT00128778 Phase 4
45 Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients Completed NCT01298193 Phase 4
46 Comparative Efficiency of Three Regimen, CEFci, CEF and EC as Neoadjuvant Chemotherapy for Primary Breast Cancer Completed NCT01199432 Phase 4
47 Symptom Management After Breast Cancer Surgery Completed NCT00686127 Phase 4
48 The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients. Completed NCT00356148 Phase 4
49 Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study Completed NCT00176046 Phase 4
50 Exercise and Phytoestrogens: Effect on Factors Predisposing to Cardiovascular Disease(CVD) in Postmenopausal Women Completed NCT01048606 Phase 4

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

39
Breast, Prostate, Whole Blood

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 91)
id Title Authors Year
1
Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population. ( 26803517 )
2016
2
Female breast cancer burden was increasing during the 40A years in Hebei Province, China: a population-based study. ( 27405613 )
2016
3
Incidence, mortality and survival of female breast cancer during 2003-2011 in Jiangsu province, China. ( 27478317 )
2016
4
Type 2 Diabetes Mellitus as a Risk Factor for Female Breast Cancer in the Population of Northern Pakistan. ( 27509959 )
2016
5
Incidence rate of female breast cancer in urban Shijiazhuang in 2012 and modifiable risk factors. ( 27766774 )
2016
6
Dietary patterns and the risk of female breast cancer among participants of the Canadian National Enhanced Cancer Surveillance System. ( 27348110 )
2016
7
Utilization of an Anti-Gravity Treadmill in a Physical Activity Program with Female Breast Cancer Survivors: A Pilot Study. ( 27293508 )
2016
8
Male Breast Cancer Incidence and Mortality Risk in the Japanese Atomic Bomb Survivors - Differences in Excess Relative and Absolute Risk from Female Breast Cancer. ( 27286002 )
2016
9
Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial. ( 27400910 )
2016
10
Female breast cancer in Central and South America. ( 27678313 )
2016
11
Single Female Breast Cancer Patients' Perspectives on Intimate Relationships. ( 27126077 )
2016
12
Study on female breast cancer imaging screening consultation network in Guangdong Province, China. ( 27172743 )
2016
13
Identification of novel serum peptides biomarkers for female breast cancer patients in Western China. ( 26705257 )
2016
14
Geographical Inequalities in Surgical Treatment for Localized Female Breast Cancer, Queensland, Australia 1997-2011: Improvements over Time but Inequalities Remain. ( 27447656 )
2016
15
Optical Screening of Female Breast Cancer from Whole Blood Using Raman Spectroscopy. ( 27634888 )
2016
16
Comparison of Clinicopathological Features and Treatments between Young (a8o40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study. ( 27031236 )
2016
17
Prediction of Female Breast Cancer Incidence among the Aging Society in Kanagawa, Japan. ( 27532126 )
2016
18
Atrial Fibrillation is Associated With Morphine Treatment in Female Breast Cancer Patients: A Retrospective Population-Based Time-Dependent Cohort Study. ( 26986153 )
2016
19
Characterization of Korean Male Breast Cancer Using an Online Nationwide Breast-Cancer Database: Matched-Pair Analysis of Patients With Female Breast Cancer. ( 27100414 )
2016
20
Role of PALB2 Polymorphisms with Regard to Susceptibility to Female Breast Cancer Risk in the Chinese Population. ( 26981788 )
2016
21
Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study. ( 26894298 )
2016
22
Geographical and Temporal Variations in Female Breast Cancer Mortality in the Municipalities of Andalusia (Southern Spain). ( 27879690 )
2016
23
Interventions to Manage Uncertainty and Fear of Recurrence in Female Breast Cancer Survivors: A Review of the Literature. ( 27857253 )
2016
24
Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis. ( 27460637 )
2016
25
Mutations in Human Interferon I+2b Gene and Potential as Risk Factor Associated with Female Breast Cancer. ( 27403569 )
2016
26
PAHs and PM2.5 emissions and female breast cancer incidence in metro Atlanta and rural Georgia. ( 26983363 )
2016
27
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. ( 27064666 )
2016
28
The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. ( 27107051 )
2016
29
Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach. ( 26905999 )
2016
30
Evaluation of Female Breast Cancer Risk Among the Betel Quid Chewer: A Bio-Statistical Assessment in Assam, India. ( 26913209 )
2015
31
OGG1 Mutations and Risk of Female Breast Cancer: Meta-Analysis and Experimental Data. ( 26089588 )
2015
32
Competing Risk Approach (CRA) for Estimation of Disability Adjusted Life Years (DALY's) for Female Breast Cancer in India. ( 26557544 )
2015
33
Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study. ( 26515910 )
2015
34
Female breast cancer in Vietnam: a comparison across Asian specific regions. ( 26487968 )
2015
35
Epidemiology, Pathological Characteristics and Estrogen and Progesterone Receptor Status of Operated Cases of Female Breast Cancer: A Retrospective Review of 266 Cases from Kerala. ( 27065660 )
2015
36
High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. ( 25909194 )
2015
37
Female Breast Cancer: Burden Of Disease In Portugal. ( 26532747 )
2015
38
Female breast cancer incidence and mortality in 2011, China. ( 26380738 )
2015
39
Germline variations of apurinic/apyrimidinic endonuclease 1 (APEX1) detected in female breast cancer patients. ( 25292033 )
2014
40
Mutation and protein expression analysis of CYP1A1 gene-a study on female breast cancer cases from India. ( 24096584 )
2014
41
GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance. ( 23266442 )
2013
42
The landscape of candidate driver genes differs between male and female breast cancer. ( 24194916 )
2013
43
Male Breast Cancer: A Population-Based Comparison with Female Breast Cancer in Hong Kong, Southern China: 1997-2006. ( 24337541 )
2013
44
Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. ( 23935206 )
2013
45
Immunohistochemical expression and mutation study of Prohibitin gene in Indian female breast cancer cases. ( 23715748 )
2013
46
Role of nuclear factor-I_B in female breast cancer: a study in Indian patients. ( 23317209 )
2012
47
Male breast cancer: A retrospective study comparing survival with female breast cancer. ( 23205077 )
2012
48
Mutational analysis of prohibitin--a highly conserved gene in Indian female breast cancer cases. ( 23244120 )
2012
49
Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. ( 21484520 )
2011
50
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. ( 21113657 )
2011

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1 12.44 AR BRCA2 CDKN1B ERBB2 KLK3 TP53
2
Show member pathways
12.41 ATM BRCA2 CDKN1B ESR1 TP53 XRCC1
3 12.38 ATM CDKN1B ERBB2 TP53
4
Show member pathways
12.13 AR ATM BRCA2 CDKN1B ERBB2 ESR1
5 12.1 ATM BRCA2 CDKN1B PHB TP53 XRCC1
6
Show member pathways
12.01 CDKN1B ERBB2 PHB TP53
7
Show member pathways
11.97 AR ERBB2 KLK3
8
Show member pathways
11.9 BRCA2 CDKN1B ERBB2 TP53
9
Show member pathways
11.82 ERBB2 ESR1 PGR
10 11.77 ATM CDKN1B ERBB2 TP53
11
Show member pathways
11.72 AR ESR1 PGR
12
Show member pathways
11.68 ATM BRCA2 TP53
13 11.62 ATM CDKN1B XRCC1
14 11.62 AR ATM BRCA2 ESR1 PHB TP53
15 11.61 ATM ERBB2 TP53
16 11.55 ATM ERBB2 TP53
17 11.54 ATM CDKN1B ESR1
18 11.41 ATM CDKN1B TP53
19 11.38 CDKN1B CYP1A1 ESR1
20 11.35 ATM CDKN1B TP53
21 11.22 BRCA2 ESR1 XRCC1
22
Show member pathways
11.22 AR CDKN1B ESR1 KLK3
23 11.11 ATM CDKN1B PGR
24
Show member pathways
10.97 ATM TP53
25 10.9 ATM TP53
26 10.72 CYP1A1 ESR1

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 AR ATM BRCA2 CDKN1B ERBB2 ESR1
2 nuclear chromosome, telomeric region GO:0000784 9.43 ATM BRCA2 XRCC1
3 protein complex GO:0043234 9.43 AR BRCA2 CDKN1B ESR1 KLK3 TP53
4 nucleoplasm GO:0005654 9.36 ADH1B AR ATM BRCA2 CDKN1B ESR1
5 cytoplasm GO:0005737 10.06 ADH1B AR ATM BRCA2 CDKN1B CYP1A1

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.92 AR BRCA2 ESR1 PHB TP53
2 DNA repair GO:0006281 9.9 ATM BRCA2 PALB2 XRCC1
3 positive regulation of gene expression GO:0010628 9.88 AR ERBB2 PHB TP53
4 cellular response to DNA damage stimulus GO:0006974 9.83 ATM BRCA2 PALB2 TP53 XRCC1
5 regulation of apoptotic process GO:0042981 9.8 ATM ESR1 PHB TP53
6 cell cycle arrest GO:0007050 9.79 ATM CDKN1B TP53
7 negative regulation of cell growth GO:0030308 9.77 CDKN1B PHB TP53
8 cell proliferation GO:0008283 9.72 AR BRCA2 CYP1A1 ERBB2 TP53
9 multicellular organism growth GO:0035264 9.69 AR ATM PALB2
10 response to hypoxia GO:0001666 9.67 ATM CDKN1B CYP1A1 XRCC1
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.65 ATM CDKN1B TP53
12 steroid hormone mediated signaling pathway GO:0043401 9.63 AR ESR1 PGR
13 response to X-ray GO:0010165 9.62 BRCA2 TP53
14 mammary gland alveolus development GO:0060749 9.61 AR ESR1
15 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 BRCA2 TP53
16 determination of adult lifespan GO:0008340 9.57 ATM TP53
17 inner cell mass cell proliferation GO:0001833 9.56 BRCA2 PALB2
18 replicative senescence GO:0090399 9.55 ATM TP53
19 positive regulation of transcription from RNA polymerase III promoter GO:0045945 9.54 AR ERBB2
20 progesterone receptor signaling pathway GO:0050847 9.4 PGR PHB
21 DNA synthesis involved in DNA repair GO:0000731 9.33 ATM BRCA2 PALB2
22 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.26 AR PGR
23 strand displacement GO:0000732 9.13 ATM BRCA2 PALB2
24 double-strand break repair via homologous recombination GO:0000724 8.92 ATM BRCA2 PALB2 XRCC1

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATPase binding GO:0051117 9.54 AR ESR1 PGR
2 protein phosphatase binding GO:0019903 9.5 CDKN1B ERBB2 TP53
3 steroid hormone receptor activity GO:0003707 9.43 AR ESR1 PGR
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.33 AR ESR1 PGR
5 enzyme binding GO:0019899 9.17 AR CYP1A1 ESR1 PGR PHB TP53
6 steroid binding GO:0005496 9.13 AR ESR1 PGR
7 protein binding GO:0005515 10.22 AR ATM BRCA2 CDKN1B CYP1A1 ERBB2

Sources for Female Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....